tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksChatGPT StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert CenterTipRanksAI
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Daily Analyst Ratings
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
ChatGPT Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

TCRR

Is TCRR a Buy, Before Earnings?
Pre-EarningsIs TCRR a Buy, Before Earnings?
12M ago
TCRR
TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
PremiumPress Releases
TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
12M ago
TCRR
Return of Adaptimmune assets complements TCR pipeline, says Guggenheim
PremiumThe Fly
Return of Adaptimmune assets complements TCR pipeline, says Guggenheim
1y ago
GSK
ADAP
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress Releases
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1y ago
TCRR
Alaunos Therapeutics appoints Hofmeister to board of directors
PremiumThe Fly
Alaunos Therapeutics appoints Hofmeister to board of directors
1y ago
TCRR
TCRT
TCR2 Therapeutics downgraded to Neutral from Buy at Mizuho
PremiumThe FlyTCR2 Therapeutics downgraded to Neutral from Buy at Mizuho
1y ago
ADAP
TCRR
TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
PremiumPress Releases
TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
1y ago
TCRR
TCR2 Therapeutics reports Q4 EPS ($1.56), consensus (79c)
PremiumThe Fly
TCR2 Therapeutics reports Q4 EPS ($1.56), consensus (79c)
1y ago
TCRR
TCR2 Therapeutics downgraded to Hold from Buy at Jefferies
PremiumThe Fly
TCR2 Therapeutics downgraded to Hold from Buy at Jefferies
1y ago
ADAP
TCRR
TCR2 Therapeutics downgraded to Hold from Buy at Truist
PremiumThe Fly
TCR2 Therapeutics downgraded to Hold from Buy at Truist
1y ago
ADAP
TCRR
TCR2 Therapeutics downgraded to Hold from Buy at Truist
PremiumThe Fly
TCR2 Therapeutics downgraded to Hold from Buy at Truist
1y ago
TCRR
TCR2 Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe Fly
TCR2 Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
1y ago
ADAP
TCRR
Adaptimmune downgraded to Hold from Buy at JonesResearch
PremiumThe FlyAdaptimmune downgraded to Hold from Buy at JonesResearch
1y ago
ADAP
TCRR
Adaptimmune Craters after Acquiring TCRR
PremiumMarket News
Adaptimmune Craters after Acquiring TCRR
1y ago
ADAP
TCRR
Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
PremiumPress Releases
Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
1y ago
TCRR
Adaptimmune, TCR2 Therapeutics to combine in all-stock transaction
PremiumThe Fly
Adaptimmune, TCR2 Therapeutics to combine in all-stock transaction
1y ago
ADAP
TCRR
TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023
PremiumPress Releases
TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023
1y ago
TCRR
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress Releases
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1y ago
TCRR
TCR2 Therapeutics price target raised to $10 from $8 at Piper Sandler
PremiumThe Fly
TCR2 Therapeutics price target raised to $10 from $8 at Piper Sandler
1y ago
TCRR
TCR² Therapeutics Announces Pipeline Priorities for 2023
PremiumPress ReleasesTCR² Therapeutics Announces Pipeline Priorities for 2023
1y ago
TCRR
TCR2 Therapeutics announces pipeline priorities for 2023
PremiumThe Fly
TCR2 Therapeutics announces pipeline priorities for 2023
1y ago
TCRR
TCR2 Therapeutics initiated with a Hold at EF Hutton
PremiumThe Fly
TCR2 Therapeutics initiated with a Hold at EF Hutton
1y ago
TCRR

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >